TABLE 2.
Interactions between DAPD and T-20 in vitroa
| Virus | CI for DAPD and T-20 at various inhibitory concentrations
|
|||
|---|---|---|---|---|
| EC50 | EC75 | EC90 | EC95 | |
| HIV-1(IIIb) X4 | 1.13 (±0.33) | 0.94 (±0.16) | 0.80 (±0.07) | 0.72 (±0.07) |
| HIV-1(14aPre) X4 | 0.85 (±0.10) | 0.83 (±0.21) | 0.84 (±0.31) | 0.91 (±0.30) |
| HIV-1(14aPost) X4 | 1.18 (±0.30) | 1.13 (±0.26) | 1.09 (±0.25) | 1.06 (±0.24) |
| HIV-1(GL-278) X4 | 0.98 (±0.23) | 0.72 (±0.20) | 0.53 (±0.18) | 0.43 (±0.16) |
| HIV-1(R5-18) R5 | 0.87 (±0.19) | 0.80 (±0.10) | 0.75 (±0.01) | 0.72 (±0.03) |
a
CI < 0.9 = synergy, CI 0.9 > 1.1 = near additivity, CI > 1.1 = antagonism. Results are an average of two to three experiments (standard deviation). Concentrations of DAPD used ranged from 0.5 to 32 μM, and those for T-20 ranged from 2.25 to 40.5 nM.